S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:AGLE

Aeglea BioTherapeutics (AGLE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$9.47
$13.76
52-Week Range
N/A
Volume
43,300 shs
Average Volume
95,409 shs
Market Capitalization
$48.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.50
AGLE stock logo

About Aeglea BioTherapeutics Stock (NASDAQ:AGLE)

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

AGLE Stock News Headlines

Bridge Biotherapeutics Inc.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Aeglea Biotherapeutics (AGLE) Gets a Buy from Stifel Nicolaus
Aeglea BioTherapeutics Announces Reverse Stock Split
Aeglea BioTherapeutics Appoints Scott Burrows As Chief Financial Officer
Aeglea BioTherapeutics (NASDAQ: AGLE)
See More Headlines
Receive AGLE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AGLE
Employees
69
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.50
High Stock Price Target
$22.50
Low Stock Price Target
$12.50
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-83,820,000.00
Net Margins
-22,195.36%
Pretax Margin
-27,931.12%

Debt

Sales & Book Value

Annual Sales
$2.33 million
Book Value
($60.61) per share

Miscellaneous

Free Float
3,782,000
Market Cap
$48.64 million
Optionable
Optionable
Beta
2.57
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Jonathan D. Alspaugh M.B.A. (Age 40)
    Strategic Advisor
    Comp: $568.55k
  • Mr. James Paul Kastenmayer J.D. (Age 51)
    Ph.D., Consultant
    Comp: $611.84k
  • Dr. Cameron Turtle DPHIL (Age 33)
    Ph.D., COO & Principal Executive Officer
  • Mr. Scott L. Burrows (Age 46)
    Chief Financial Officer
  • Joey Perrone
    Vice President of Finance & Investor Relations
  • Ms. Heidy Abreu King-Jones J.D. (Age 40)
    L.L.M., Chief Legal Officer & Corporate Secretary
  • Dr. Kelly Boothe Ph.D.
    Senior Director of Corporate Communications & Investor Relations

AGLE Stock Analysis - Frequently Asked Questions

Should I buy or sell Aeglea BioTherapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AGLE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGLE, but not buy additional shares or sell existing shares.
View AGLE analyst ratings
or view top-rated stocks.

What is Aeglea BioTherapeutics' stock price target for 2024?

4 Wall Street analysts have issued 1 year price targets for Aeglea BioTherapeutics' stock. Their AGLE share price targets range from $12.50 to $22.50. On average, they expect the company's stock price to reach $17.50 in the next twelve months.
View analysts price targets for AGLE
or view top-rated stocks among Wall Street analysts.

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) released its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($7.75) EPS for the quarter, missing analysts' consensus estimates of ($7.00) by $0.75. The biotechnology company earned $1.40 million during the quarter, compared to analyst estimates of $1.38 million. Aeglea BioTherapeutics had a negative net margin of 22,195.36% and a negative trailing twelve-month return on equity of 132.05%.

When did Aeglea BioTherapeutics' stock split?

Shares of Aeglea BioTherapeutics reverse split on Friday, September 8th 2023. The 1-25 reverse split was announced on Thursday, September 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?

3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aeglea BioTherapeutics own?
When did Aeglea BioTherapeutics IPO?

Aeglea BioTherapeutics (AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

Who are Aeglea BioTherapeutics' major shareholders?

Aeglea BioTherapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anthony G Quinn, Armen Shanafelt, Jonathan Alspaugh, Jr Michael Conick Hanley and Marcio Souza.
View institutional ownership trends
.

This page (NASDAQ:AGLE) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners